Menu Search
Equities

Pharmacielo Ltd

PCLOF:PKC

Pharmacielo Ltd

Actions
  • Price (USD)0.0563
  • Today's Change-0.001 / -1.23%
  • Shares traded1.58k
  • 1 Year change-55.21%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 19:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PharmaCielo Ltd. is a Canada-based company with a focus on ethical and sustainable processing and supplying of all natural, pharmaceutical-grade medical cannabis products to channel distributors. The Company has two subsidiaries, PharmaCielo Colombia Holdings S.A.S. (PharmaCielo Colombia) and Ubiquo Telemedicina S.A.S. (Ubiquo). PharmaCielo Colombia cultivates and processes the Company’s all-natural cannabis into standardized, medicinal-grade oil extracts and related products. In Colombia, PharmaCielo Colombia is a licensed cultivator, producer, and distributor of both TetraHydroCannabinol (THC) and Cannabidiol (CBD) medical cannabis for use in Colombia, international export, and research purposes. Ubiquo is a knowledge management and medical consultation system that focuses on creating access to healthcare for Colombians. Ubiquo is a technology platform and a user interface that allows doctors and patients to communicate. Ubiquo is used as a communication tool.

  • Revenue in CAD (TTM)1.62m
  • Net income in CAD-14.15m
  • Incorporated2017
  • Employees268.00
  • Location
    Pharmacielo Ltd82 Richmond Street EastTORONTO M5C 1P1CanadaCAN
  • Phone+1 (416) 315-8741
  • Fax+1 (416) 315-8741
  • Websitehttps://www.pharmacielo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.